Investing.com -- Senti Biosciences (NASDAQ:SNTI) stock surged 29% after the company reported positive clinical trial results for its cancer therapy SENTI-202 and received FDA Regenerative Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback